We are live on
!
Find out more
EHI
Eagle Health Investments Portfolio holdings
AUM
$572M
1-Year Est. Return
67.49%
This Fund
S&P 500
This Quarter
Est. Return
+41.7%
1 Year Est. Return
+67.49%
3 Year Est. Return
+165.01%
5 Year Est. Return
+204.84%
10 Year Est. Return
–
AUM
$455M
AUM Growth
+$74.1M
(+19%)
Cap. Flow
-$12.9M
Cap. Flow
% of AUM
-2.84%
Top 10 Holdings %
Top 10 Hldgs %
70.66%
Holding
34
New
11
Increased
3
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$11.7M |
| 2 |
Icon
ICLR
|
+$11.5M |
| 3 |
Kymera Therapeutics
KYMR
|
+$9.2M |
| 4 |
AtaiBeckley Inc
ATAI
|
+$7.92M |
| 5 |
uniQure
QURE
|
+$7.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$21M |
| 2 |
argenx
ARGX
|
+$12.6M |
| 3 |
Insmed
INSM
|
+$11.1M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$10.8M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
argenx
ARGX
$54.8B
| $52.8M | 11.59% |
62,730
-14,700
| -19% | -$12.6M |
|
|
2
Icon
ICLR
$12.4B
| $45M | 9.89% |
247,090
+64,500
| +35% | +$11.5M |
|
3
Natera
NTRA
$38B
| $42M | 9.23% |
183,264
-20,400
| -10% | -$4.26M |
|
|
4
Insmed
INSM
$28.9B
| $36.7M | 8.07% |
210,900
-60,700
| -22% | -$11.1M |
|
5
Illumina
ILMN
$29.3B
| $30.3M | 6.66% |
231,161
-91,100
| -28% | -$10.7M |
|
6
Guardant Health
GH
$21.1B
| $29M | 6.38% |
284,100
| – | – |
|
7
Neurocrine Biosciences
NBIX
$16.2B
| $23.1M | 5.07% |
162,800
| – | – |
|
8
BioMarin Pharmaceuticals
BMRN
$11.9B
| $21.8M | 4.79% |
366,812
| – | – |
|
9
Fortrea Holdings
FTRE
$1.68B
| $21M | 4.62% |
1,218,560
+229,788
| +23% | +$2.84M |
|
10
BridgeBio Pharma
BBIO
$16.2B
| $19.8M | 4.36% |
259,300
| – | – |
|
11
Scholar Rock
SRRK
$6.41B
| $16M | 3.52% |
363,300
| – | – |
|
|
EXAS
12
DELISTED
Exact Sciences
EXAS
| $15M | 3.3% |
147,750
-123,200
| -45% | -$9.89M |
|
|
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
| $11.1M | 2.44% |
+275,090
| New | +$6.36M |
|
|
14
Kymera Therapeutics
KYMR
$8.85B
| $10.6M | 2.33% |
+136,300
| New | +$9.2M |
|
|
CMPS
15
Compass Pathways
CMPS
$1.83B
| $10.5M | 2.3% |
1,519,388
+583,938
| +62% | +$3.56M |
|
16
Procept Biorobotics
PRCT
$1.15B
| $9.7M | 2.13% |
308,434
| – | – |
|
17
Revolution Medicines
RVMD
$42.4B
| $9.23M | 2.03% |
+115,900
| New | +$7.6M |
|
|
18
Legend Biotech
LEGN
$3.73B
| $8.88M | 1.95% |
+408,652
| New | +$11.7M |
|
|
19
AtaiBeckley Inc
ATAI
$2.66B
| $6.86M | 1.51% |
+1,678,400
| New | +$7.92M |
|
|
SLNO
20
DELISTED
Soleno Therapeutics
SLNO
| $6.26M | 1.37% |
+135,100
| New | +$7.41M |
|
21
Protagonist Therapeutics
PTGX
$9.46B
| $5M | 1.1% |
+57,300
| New | +$4.69M |
|
|
22
uniQure
QURE
$3.15B
| $4.91M | 1.08% |
+205,247
| New | +$7.92M |
|
23
Praxis Precision Medicines
PRAX
$10.3B
| $4.41M | 0.97% |
+14,951
| New | +$2.78M |
|
|
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
| $2.58M | 0.57% |
103,100
| – | – |
|
25
Intuitive Surgical
ISRG
$132B
| $2.49M | 0.55% |
4,390
| – | – |
|
Similar funds
NA
MAM
MW
BSG
RI
XI
PSH
NWA
Eagle Health Investments's Q4 2025 Portfolio in Review
As of Q4 2025, Eagle Health Investments held 34 positions worth $455M, up 19% from $381M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Eagle Health Investments's Q4 2025 filing shows 11 new, 3 increased, 5 reduced and 4 closed positions. Its largest new stake was Legend Biotech: 408,652 shares worth $8.88M. The largest sale was Ultragenyx Pharmaceutical, an estimated $21M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Eagle Health Investments's largest Q4 2025 buy was Legend Biotech: 408,652 shares worth $8.88M.
- Eagle Health Investments added most to Icon in Q4 2025, an estimated $11.5M increase.
- Eagle Health Investments's biggest Q4 2025 reduction was argenx, cutting an estimated $12.6M.
- Eagle Health Investments fully exited Ultragenyx Pharmaceutical in Q4 2025, selling an estimated $21M.
- Eagle Health Investments's ten largest holdings make up 71% of its $455M portfolio in Q4 2025.
- Eagle Health Investments opened 11 new positions and closed 4 in Q4 2025.
- Eagle Health Investments's portfolio value rose 19% quarter-over-quarter to $455M.
Based on Eagle Health Investments's 13F filing for Q4 2025, filed 6 Feb 2026.